Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.K. in Agreements for Merck/Ridgeback, Pfizer Covid-19 Antivirals in Development

10/20/2021 | 12:58pm EST

By Josh Beckerman

The U.K. government has reached agreements to secure two Covid-19 antiviral treatments being developed, one by Merck & Co. with Ridgeback Biotherapeutics and one by Pfizer Inc.

The government secured 480,000 courses of molnupiravir, from Merck and Ridgeback, and 250,000 courses of Pfizer's PF-07321332/ritonavir.

The most vulnerable people would be eligible first, including the elderly and those with weakened immune systems, the government said.

A U.S. Food and Drug Administration advisory committee is expected to meet Nov. 30 to discuss the pill from Merck and Ridgeback. On Wednesday, the Bill & Melinda Gates Foundation announced today a commitment of up to $120 million to accelerate access to the drug for lower-income countries.

The U.K. government said the antiviral drugs "will be particularly vital in protecting those who may not get the same antibody response to the vaccines as the majority of the population."

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

10-20-21 1458ET

Stocks mentioned in the article
ChangeLast1st jan.
MERCK & CO., INC. -3.79% 79.16 Delayed Quote.-3.23%
PFIZER, INC. 6.11% 54 Delayed Quote.46.70%
All news about MERCK & CO., INC.
10:06aNew Analysis Shows Merck COVID-19 Pill Molnupiravir Less Effective Than Previously Repo..
MT
08:51aMerck & Co. Says Molnupiravir Cuts Risk of Severe COVID-19 Based on Trial Data
MT
07:41aMerck, Ridgeback Biotherapeutics' Molnupiravir Drug Reduced Risk of Severe COVID-19 Bas..
MT
06:46aMerck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Mo..
BU
05:56aUK To Test Merck & Co.'s COVID-19 Pill In National Study
MT
03:46aPfizer, Merck Reportedly Agree to License Production of Respective Experimental COVID-1..
MT
02:07aPfizer, Merck & Co. Set to Allow Vietnamese Companies to Produce COVID-19 Pill
MT
11/24Truist Securities Adjusts Merck's Price Target to $95 From $92, Reiterates Buy Rating
MT
11/24Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
BU
11/24Gilead Sciences, Merck Pause Phase 2 HIV Trial
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 600 M - -
Net income 2021 13 638 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 16,3x
Yield 2021 3,28%
Capitalization 200 B 200 B -
EV / Sales 2021 4,54x
EV / Sales 2022 3,78x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 79,16 $
Average target price 96,70 $
Spread / Average Target 22,2%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-3.23%207 835
JOHNSON & JOHNSON1.82%421 847
ROCHE HOLDING AG17.17%334 769
PFIZER, INC.38.25%285 639
NOVO NORDISK A/S68.76%247 704
ELI LILLY AND COMPANY55.18%237 527